Overall survival (OS) results from the phase III PHENIX trial of HER2+metastatic breast cancer treated with pyrotinib plus capecitabineZefei Jiang,Min Yan,Li Bian,Tao Wang,Xichun Hu,Qingyuan Zhang,Quchang Ouyang,Jifeng Feng,Yongmei Yin,Tao Sun,Zhongsheng Tong,Xiaojia Wang,Herui Yao,Shuping Jiang,Xiaoyu Zhu,Jianjun ZouCANCER RESEARCH(2022)引用 2|浏览18暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要